Clinical trial · Interventional
Helping Cancer Patients Manage Neuropathy Symptoms From Chemotherapy With a Low-Intensity, Low-Risk Cranial PEMF Device
Evaluating the Safety and Effectiveness of a Low Intensity Cranial PEMF Device in Improving Chemotherapy Induced Peripheral Neuropathy Symptoms
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The goal of this clinical trial is to examine a low-intensity, low-risk cranial PEMF device and its effectiveness with helping cancer patients manage neuropathy symptoms from chemotherapy. Eligible patients are individuals who have been diagnosed with chemotherapy-induced peripheral neuropathy or are experiencing pain due to chemotherapy and are eighteen to sixty. The main questions the study aims to answer are: To examine whether the application of low intensity, low frequency PEMF (by the System for Heterogeneous Integrated magnetic Field Transmission (SHIFT)) results in a significant decrease in neuropathic pain intensity. To examine if SHIFT results in a decrease of pain related interference and associated symptoms of CIPN. Researchers will compare an active, treatment arm to a placebo, SHAM arm. Participants will be required to use the device once daily, fill out daily, weekly, and monthly surveys. They will have to do one blood draw at the beginning of the study and one at the end of the study.
Conditions
Conditions (4)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Chemotherapy Induced Neuropathic Pain | — | UNRESOLVED | — |
| Chemotherapy Induced Pain Neuropathy | — | UNRESOLVED | — |
| Chemotherapy Induced Peripheral Neuropathy | — | UNRESOLVED | — |
| Chemotherapy Induced Peripheral Neuropathy (CIPN) | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| SHIFT | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Treatment Device
- interventionNames
- Device: SHIFT
- type
- SHAM_COMPARATOR
- label
- Sham Device
- interventionNames
- Device: SHIFT
Primary outcomes (3)
- measure
- Decrease in Neuropathic Pain Intensity
- timeFrame
- 12 weeks
- description
- Measured through scores in the Neuropathy Pain Scale. The Neuropathy Pain Scale uses a range a 0 to 10, with 0 being no pain/sensation and 10 being the most intense pain/sensation imaginable.
- measure
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 60 Years
Show eligibility criteria text
Inclusion Criteria: * Able to use smart phone and willing to receive text messages/emails * Has CIPN disorder/neuropathic pain related to chemotherapy * Able and willing to follow instructions * Not participated in any other clinical study within the past two months that may influence the results of this study Exclusion Criteria: * History of seizures * Hydrocephalic * Had a change in medical therapy related to the treatment of neuropathy or chronic pain in the last fourteen days * Received repetitive transcranial magnetic stimulation (rTMS) in the last 60 days * Implanted device or metal in the brain * History of brain bleed in the last six months * History of suicidal behavior, bipolar disorder, schizophrenia * Active radiation over the scalp * Brain metastases * Currently participates in other neuropathic pain studies * Has any other medical condition that would prevent them from participating, including scalp wounds, hyperhidrosis, sensitive scalp, rash * Pregnant
References
Publications (0)
Data not yet available